Abstract:Given the limitations of existing therapeutic agents for treatment of postmenopausal osteoporosis, there still remains a need for more options with both efficacy and less adverse effects. Cistanche deserticola Y. C. Ma is known as a popular tonic herb traditionally used to treatment deficiency of kidney energy including muscle weakness in minority area of Asian counties. Based on the theory of "kidney dominate bone," an ovariectomized (OVX) rat model of postmenopausal osteoporosis was used to evaluate the therapeutic effect of C. deserticola extract (CDE) on bone loss. Forty eight female Sprague-Dawley rats, aged about 12 weeks, were randomly assigned into six groups including sham group orally administrated with 0.5% carboxymethyl cellulose sodium (CMC-Na) (sham), positive group treated with 1 mg/kg of estradiol valerate (EV), low, moderate, and high dosage groups orally administrated with 200, 400, and 800 mg/kg/day of CDE, respectively. After 3 months of continuous intervention, CDE exhibited significant anti-osteoporotic activity evidenced by the enhanced total bone mineral density, ameliorated bone microarchitecture; increased alkaline phosphatase activity; decreased deoxypyridinoline, cathepsin K, tartrate-resistant acid phosphatase, and malondialdehyde levels; whereas the body, uterus, and vagina weights in OVX rats were not influenced by CDE intervention. In addition, a seemed contradictory phenomenon on levels of calcium and phosphorus between OVX and sham rats were observed and elucidated. Mechanistically, CDE significantly down-regulated the levels of TRAF6, RANKL, RANK, NF-κB, IKKβ, NFAT2, and up-regulated the phosphatidylinositol 3-kinase (PI3K), AKT, osteoprotegerin, and c-Fos expressions, which implied CDE could suppress RANKL/RANK-induced activation of downstream NF-κB and PI3K/AKT pathways, and ultimately, preventing activity of the key osteoclastogenic proteins NFAT2 and c-Fos. All of the data suggested CDE possessed potential anti-osteoporotic activity and this effect was, at least in part, involved in modulation of RANKL/RANK/TRAF6-mediated NF-κB and PI3K/AKT signaling as well as c-Fos and NFAT2 levels. Therefore, CDE may represent a useful promising remedy candidate for treatment of postmenopausal osteoporosis.

Bu-Shen-Ning-Xin decoction suppresses osteoclastogenesis via increasing dehydroepiandrosterone to prevent postmenopausal osteoporosis

Bu-Shen-Ning-Xin Decoction: Inhibition of Osteoclastogenesis by Abrogation of the Rankl-Induced Nfatc1 and Nf-Kappa B Signaling Pathways Via Selective Estrogen Receptor Alpha

Bu‑Shen‑Ning‑Xin Decoction Suppresses Osteoclastogenesis by Modulating RANKL/OPG Imbalance in the CD4+ T Lymphocytes of Ovariectomized Mice.

BSNXD Modulates Mesenchymal Stem Cell Differentiation into Osteoblasts in a Postmenopausal Osteoporotic Mouse Model.

Erxian decoction potentially prevents postmenopausal osteoporosis by modulating miR-335: a study based on bioinformatics analysis and preliminary clinical case validation

Bu-Shen-Ning-Xin Decoction Ameliorated the Osteoporotic Phenotype of Ovariectomized Mice Without Affecting the Serum Estrogen Concentration or Uterus.

Predominant Effect of Bushen Ningxin Decoction on Postmenopausal Osteoporosis in Mice

Bu-Shen-Ning-Xin decoction inhibits macrophage activation to ameliorate premature ovarian insufficiency-related osteoimmune disorder via FSH/FSHR pathway

Efficacy and Safety of Denosumab in Postmenopausal Women with Osteoporosis

Effect of Bushen Ningxin Decoction on Proliferation and Apoptosis of Murine Osteoblast

Bushen Ningxin Decoction Pharmacological Serum Promotes the Proliferation and Suppresses the Apoptosis of Murine Osteoblasts Through MAPK Pathway.

Effects of Bu-Shen-Ning-Xin Decoction on Immune Cells of the Spleen and Bone Marrow in Ovariectomized Mice

Dehydroepiandrosterone Inhibited the Bone Resorption Through the Upregulation of OPG/RANKL.

Bu-Gu-Sheng-Sui Decoction Promotes Osteogenesis Via Activating the ERK/Smad Signaling Pathways.

Quantitative Proteomics Revealed the Pharmacodynamic Network of Bugu Shengsui Decoction Promoting Osteoblast Proliferation

Up-regulation of ERβ in Murine Osteoblasts with the Action of Dehydroepiandrosterone

DHEA Prevents Bone Loss by Suppressing the Expansion of CD4(+) T Cells and TNFa Production in the OVX-mouse Model for Postmenopausal Osteoporosis.

Traditional Chinese Medicine Bushen-Jianpi-Huoxue Decoction Prevents Diabetic Osteoporosis in Rats Via Wnt and Nuclear Factor-Kappa B Signaling Pathways.

Anti-Osteoporotic Activity of an Edible Traditional Chinese Medicine Cistanche deserticola on Bone Metabolism of Ovariectomized Rats Through RANKL/RANK/TRAF6-Mediated Signaling Pathways

Dendrobium officinale Orchid Extract Prevents Ovariectomy-Induced Osteoporosis in Vivo and Inhibits RANKL-Induced Osteoclast Differentiation in Vitro

Antiosteoporotic Effects and Proteomic Characterization of the Target and Mechanism of an Er-Xian Decoction on Osteoblastic UMR-106 and Osteoclasts Induced from RAW264.7